225 related articles for article (PubMed ID: 16296804)
21. [Effect of PTH on bone structural properties].
Ito M
Clin Calcium; 2012 Mar; 22(3):335-41. PubMed ID: 22370300
[TBL] [Abstract][Full Text] [Related]
22. Two osteoporosis treatments deemed best for brittle bones. Sequential therapy of two drugs, bisphosphonates and PTH, produces the best effects on bone strength.
Health News; 2006 Feb; 12(2):3-4. PubMed ID: 16453932
[No Abstract] [Full Text] [Related]
23. [Drug delivery system for the treatment of osteoporosis].
Satoh T; Yoshida G; Orito Y; Koike T
Nihon Rinsho; 1998 Mar; 56(3):742-7. PubMed ID: 9549367
[TBL] [Abstract][Full Text] [Related]
24. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
25. Parathyroid hormone update.
Hamann KL; Lane NE
Rheum Dis Clin North Am; 2006 Nov; 32(4):703-19. PubMed ID: 17288973
[TBL] [Abstract][Full Text] [Related]
26. [Regulation of bone mineralization by parathyroid hormone].
Shimizu M; Tamura T
Clin Calcium; 2004 Jun; 14(6):70-5. PubMed ID: 15577058
[TBL] [Abstract][Full Text] [Related]
27. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength.
Fox J; Miller MA; Newman MK; Metcalfe AF; Turner CH; Recker RR; Smith SY
Calcif Tissue Int; 2006 Oct; 79(4):262-72. PubMed ID: 16969596
[TBL] [Abstract][Full Text] [Related]
28. Parathyroid hormone as an anabolic therapy for women and men.
Bilezikian JP; Rubin MR; Finkelstein JS
J Endocrinol Invest; 2005; 28(8 Suppl):41-9. PubMed ID: 16329201
[TBL] [Abstract][Full Text] [Related]
29. Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure.
Compston JE
Bone; 2007 Jun; 40(6):1447-52. PubMed ID: 17045858
[TBL] [Abstract][Full Text] [Related]
30. [Therapeutic agents for disorders of bone and calcium metabolism--Teriparatide, parathyroid hormone (1-34) as a daily subcutaneous injection].
Hashimoto Y; Wakayama N; Miyauchi A
Clin Calcium; 2007 Jan; 17(1):48-55. PubMed ID: 17211093
[TBL] [Abstract][Full Text] [Related]
31. [PTH preparations].
Fukumoto S
Nihon Rinsho; 2015 Oct; 73(10):1696-700. PubMed ID: 26529932
[TBL] [Abstract][Full Text] [Related]
32. The teriparatide in the treatment of severe senile osteoporosis.
Manuele S; Sorbello L; Puglisi N; Grasso S; La Malfa L; D'Urbino G; Rizzotto M; Strano S; Maugeri D
Arch Gerontol Geriatr; 2007; 44 Suppl 1():249-58. PubMed ID: 17317460
[TBL] [Abstract][Full Text] [Related]
33. Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism - translating the pharmacology.
Tay D; Cremers S; Bilezikian JP
Br J Clin Pharmacol; 2018 Feb; 84(2):252-267. PubMed ID: 29049872
[TBL] [Abstract][Full Text] [Related]
34. Preparation and in vivo evaluation of an orally available enteric-microencapsulated parathyroid hormone (1-34)-deoxycholic acid nanocomplex.
Hwang SR; Seo DH; Byun Y; Park JW
Int J Nanomedicine; 2016; 11():4231-46. PubMed ID: 27621618
[TBL] [Abstract][Full Text] [Related]
35. Parathyroid hormone in the treatment of osteoporosis.
Fujita T
BioDrugs; 2001; 15(11):721-8. PubMed ID: 11707147
[TBL] [Abstract][Full Text] [Related]
36. [Treatment of primary osteoporosis in men].
Yamaguchi T; Sugimoto T
Clin Calcium; 2006 Mar; 16(3):474-9. PubMed ID: 16508131
[TBL] [Abstract][Full Text] [Related]
37. [PTH].
Shimizu M
Clin Calcium; 2002 Aug; 12(8):1148-51. PubMed ID: 15775412
[TBL] [Abstract][Full Text] [Related]
38. [Therapeutic agents for disorders of bone and calcium metabolism. Development of nasal formulation of hPTH (1-34)].
Sato K
Clin Calcium; 2007 Jan; 17(1):64-71. PubMed ID: 17211095
[TBL] [Abstract][Full Text] [Related]
39. New mechanisms and targets in the treatment of bone fragility.
Martin TJ; Seeman E
Clin Sci (Lond); 2007 Jan; 112(2):77-91. PubMed ID: 17155930
[TBL] [Abstract][Full Text] [Related]
40. Compliance and persistence with treatment with parathyroid hormone for osteoporosis. A Danish national register-based cohort study.
Thorsteinsson AL; Vestergaard P; Eiken P
Arch Osteoporos; 2015; 10():35. PubMed ID: 26427867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
